{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:37:59Z","timestamp":1792643879401,"version":"4.5.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The association of tamoxifen use with the risk of uterine diseases, such as endometrial cancer, in premenopausal women with breast cancer remains controversial. However, many studies have reported an increased risk of uterine disease among postmenopausal tamoxifen users.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the association of tamoxifen use with the risk of endometrial cancer and other uterine diseases in premenopausal women with breast cancer.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>A nationwide, population-based, retrospective longitudinal cohort study with an 18-year study period was conducted using data obtained from the Korean National Health Insurance Service. Participants included premenopausal women aged 20 to 50 years with breast cancer diagnoses between January 2003 and December 2018. Data were analyzed from April to December 2021.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Tamoxifen treatment.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The incidence of uterine diseases, including endometrial cancer, hyperplasia, polyps, and other uterine cancers, was identified in the study cohort using insurance claim codes. The incidence of uterine diseases per 1000 person-years was compared between women receiving tamoxifen and those not treated with adjuvant hormone therapy. Multivariable Cox proportional hazard regression analysis was performed to determine the risk of each uterine disease.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 78\u202f320 female participants with a mean (SD) age of 42.1 (6.1) years, 34\u202f637 (44.2%) were categorized into the tamoxifen group and 43\u202f683 (55.8%) were categorized into the control group. Among tamoxifen users, during the mean (SD) follow-up duration of 6.13 (4.15) years, the incidence of newly diagnosed endometrial polyps was 20.13 cases per 1000 person-years, that of endometrial hyperplasia was 13.49 cases per 1000 person-years, that of endometrial cancer was 2.01 cases per 1000 person-years, and that of other uterine cancers was 0.45 cases per 1000 person-years. The risk of endometrial cancer was higher in the tamoxifen group than in the control group (hazard ratio, 3.77; 95% CI, 3.04-4.66) after adjusting for age, body mass index, history of diabetes, hypertension, dyslipidemia, polycystic ovary syndrome, gonadotropin-releasing hormone agonist treatment, and trastuzumab treatment.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this longitudinal cohort study, premenopausal Korean women with breast cancer who received tamoxifen as adjuvant hormone therapy had a significantly increased risk of endometrial hyperplasia, polyps, carcinoma, and other uterine cancers compared with those who were not treated with adjuvant hormone therapy. These findings suggest that clinicians should consider the risk of uterine disease among tamoxifen users, including premenopausal women.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.43951","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T16:34:51Z","timestamp":1669653291000},"page":"e2243951","source":"Crossref","is-referenced-by-count":64,"title":["Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer"],"prefix":"10.1001","volume":"5","author":[{"given":"Ki-Jin","family":"Ryu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Korea University Anam Hospital, Korea University College of Medicine, Seongbuk-gu, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Sun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Korea University Anam Hospital, Korea University College of Medicine, Seongbuk-gu, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Korea University Anam Hospital, Korea University College of Medicine, Seongbuk-gu, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghyun","family":"Nam","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Korea University Anam Hospital, Korea University College of Medicine, Seongbuk-gu, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Gyeong","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Korea University Anam Hospital, Korea University College of Medicine, Seongbuk-gu, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Korea University Anam Hospital, Korea University College of Medicine, Seongbuk-gu, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuntae","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Korea University Anam Hospital, Korea University College of Medicine, Seongbuk-gu, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"issue":"6","key":"zoi221239r1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.v68.6","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"zoi221239r2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1067\/mob.2000.105941","article-title":"Drugs for the gynecologist to prescribe in the prevention of breast cancer: current status and future trends.","volume":"182","author":"Goldstein","year":"2000","journal-title":"Am J Obstet Gynecol"},{"issue":"22","key":"zoi221239r4","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer.","volume":"339","author":"Osborne","year":"1998","journal-title":"N Engl J Med"},{"issue":"9114","key":"zoi221239r5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists\u2019 Collaborative Group.","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"zoi221239r6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/02841860601034834","article-title":"Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer.","volume":"46","author":"Rutqvist","year":"2007","journal-title":"Acta Oncol"},{"issue":"5","key":"zoi221239r7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/jnci\/dji057","article-title":"Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.","volume":"97","author":"Swerdlow","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"zoi221239r8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.gyobfe.2007.10.006","article-title":"Uterine abnormalities in non menopausal women who received tamoxifen for breast cancer adjuvant therapy [in French].","volume":"35","author":"d\u2019Arailh","year":"2007","journal-title":"Gynecol Obstet Fertil"},{"issue":"4","key":"zoi221239r9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3802\/jgo.2008.19.4.256","article-title":"The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients.","volume":"19","author":"Kim","year":"2008","journal-title":"J Gynecol Oncol"},{"key":"zoi221239r10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1471-2407-12-161","article-title":"A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.","volume":"12","author":"Gu","year":"2012","journal-title":"BMC Cancer"},{"issue":"1","key":"zoi221239r11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5468\/ogs.2017.60.1.26","article-title":"Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen.","volume":"60","author":"Jeon","year":"2017","journal-title":"Obstet Gynecol Sci"},{"issue":"6","key":"zoi221239r12","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/01.AOG.0000450757.18294.cf","article-title":"Committee opinion no. 601: tamoxifen and uterine cancer.","volume":"123","author":"Committee on Gynecologic Practice","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"2","key":"zoi221239r14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4048\/jbc.2020.23.e24","article-title":"Breast cancer statistics in Korea in 2017: data from a breast cancer registry.","volume":"23","author":"Kang","year":"2020","journal-title":"J Breast Cancer"},{"issue":"3","key":"zoi221239r15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/ije\/dyw253","article-title":"Data resource profile: the national health information database of the National Health Insurance Service in South Korea.","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"13","key":"zoi221239r16","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/cncr.29332","article-title":"Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.","volume":"121","author":"Chlebowski","year":"2015","journal-title":"Cancer"},{"key":"zoi221239r17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.636378","article-title":"Risk of endometrial cancer and frequencies of invasive endometrial procedures in young breast cancer survivors treated with tamoxifen: a nationwide study.","volume":"11","author":"Choi","year":"2021","journal-title":"Front Oncol"},{"issue":"9793","key":"zoi221239r18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"zoi221239r19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ctrv.2011.06.009","article-title":"Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.","volume":"38","author":"Iqbal","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"zoi221239r20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/tcmj.tcmj_17_19","article-title":"Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: a population-based study in Taiwan.","volume":"32","author":"Chu","year":"2019","journal-title":"Ci Ji Yi Xue Za Zhi"},{"issue":"4","key":"zoi221239r21","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.ajog.2004.12.083","article-title":"Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.","volume":"192","author":"Chalas","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"18","key":"zoi221239r22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"zoi221239r23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"zoi221239r24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1634\/theoncologist.2014-0047","article-title":"Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study.","volume":"19","author":"Lin","year":"2014","journal-title":"Oncologist"},{"issue":"11","key":"zoi221239r25","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1158\/1055-9965.EPI-11-0715","article-title":"Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer.","volume":"20","author":"Friedenreich","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"zoi221239r26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071766","article-title":"Endocrine risk factors of endometrial cancer: polycystic ovary syndrome, oral contraceptives, infertility, tamoxifen.","volume":"12","author":"Ignatov","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"zoi221239r27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/cells10020292","article-title":"The role of gonadotropin-releasing hormone (GnRH) in endometrial cancer.","volume":"10","author":"Emons","year":"2021","journal-title":"Cells"},{"key":"zoi221239r28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bpobgyn.2020.05.003","article-title":"Progesterone and endometrial cancer.","volume":"69","author":"Gompel","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"zoi221239r3","unstructured":"National Comprehensive Cancer Network. Breast cancer. Accessed April 20, 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419?"},{"key":"zoi221239r13","unstructured":"American Cancer Society. Hormone therapy for breast cancer. Accessed April 20, 2022. https:\/\/www.cancer.org\/cancer\/breast-cancer\/treatment\/hormone-therapy-for-breast-cancer.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2799011\/ryu_2022_oi_221239_1668781317.03418.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T16:34:55Z","timestamp":1669653295000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2799011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.43951","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]}}}